CA
Freya Biosciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Microbial Immunotherapy for IVF | Infertility / Poor IVF Outcomes due to Inflammatory Dysbiosis | Phase 2 |
| Microbial Immunotherapy for Endometriosis | Endometriosis-Associated Infertility | Phase 2 |
| Microbial Immunotherapy for Preterm Birth | Prevention of Spontaneous Preterm Birth | Phase 2 |
Leadership Team at Freya Biosciences
JV
Johan van Hylckama Vlieg
CSO, Co-Founder
UB
Ulrich Binné
CBO, Co-Founder
PC
Per Cantor
CMO
CL
Crilles Larsen
CTO